11/27/21, 5:18 AM RePORT ) RePORTER

**∢** Back to Search Results

**Description** 









Patents

**Outcomes** 

Clinical Studies

News and More

History

🞾 <u>Similar Projects</u>

## **JAK-STAT Control of Zika Virus-Induced Fetal Injury**

Project Number Contact PI/Project Leader
1R01AI143265-01A1 ADAMS WALDORF, KRISTINA
M.Other PIs

Awardee Organization
UNIVERSITY OF WASHINGTON

Ø. Suare ▲



#### **Abstract Text**

PROJECT SUMMARY/ABSTRACT The recent epidemic of Zika virus (ZIKV) in the Americas was deemed a global public health emergency after an unexpected surge in congenital microcephaly cases suggested that the virus was teratogenic in pregnancy. ZIKV is a flavivirus, primarily transmitted to humans by the bite of infected mosquitoes. ZIKV can infect a variety of placental cells and is also highly neurotropic to target neural progenitor cells, astrocytes and neurons in all stages of development. The congenital ZIKV syndrome describes a severe pattern of placental and fetal brain injury associated with pregnancy infection including microcephaly, ventriculomegaly, and ocular injury. Although the epidemic is now in decline, outbreaks will recur and the US remains at risk for an epidemic. Thus, an enduring need remains to define the viral-host interactions that support ZIKV infection, replication, and maternal-fetal transmission, and to develop a clinically relevant animal model for studies of pathogenesis. Relevant animal models are essential to define the outcome of viral-host interaction within the progression of ZIKV infection and to evaluate the efficacy of vaccines and therapeutics to control ZIKV infection and emergence. We have developed a highly relevant nonhuman primate model of the congenital ZIKV syndrome (Macaca nemestrina, pigtail macaque) in addition to clinically relevant in vitro and ex vivo models of placental and neural stem cell infection. We have shown that ZIKV (1) mediates a broad blockade to the JAK-STAT pathway in infected cells to abrogate cytokine signaling mediated by STATs 1-6, to suppress interferon antiviral defenses; (2) infects trophoblast, myeloid, epithelial, and neural progenitor cells to impose a JAK-STAT blockade through the actions of viral nonstructural protein(s); (3) infects a variety of maternal and fetal tissues in our nonhuman primate model including the neural progenitor cells in the developing fetal brain, and (4) infection reprograms the STAT-dependent fetal brain transcriptome in vivo to alter developmental gene networks. In this resubmission, we present new preliminary data to reveal that ZIKV NS5 binding to HSP90 disrupts the essential interaction of Jak and Tyk2 kinases with HSP90 that otherwise promotes kinase folding and function. The ZIKV NS5-HSP90 interaction suppresses JAK-STAT signaling to abrogate interferon antiviral defenses, which also presents a blockade to cytokine-directed cell-fate decisions signaled via the JAK-STAT pathway that, in part, underlie ZIKV disease. Our central hypothesis is that acute ZIKV infection induces a broad blockade of JAK-STAT signaling involving multiple STATs to suppress antiviral defenses, which enhances vertical transmission and alters fetal brain development. In Aim 1, we will determine how ZIKV mediates a broad JAK-STAT signaling suppression (STAT 1-6) in vitro and ex vivo to control innate immune defenses, viral trafficking and injury. A new feature of Aim 1 is that we will define the outcome of ZIKV NS5 binding to host cell HSP90, which we hypothesize will disrupt client Jak and Tyk2 kinase actions. In Aim 2, we will determine how viral control of JAK-STAT impacts vertical transmission and pathogenesis of fetal brain injury in vivo in a nonhuman primate model of the congenital ZIKV syndrome.

#### **Public Health Relevance Statement**

PROJECT NARRATIVE The goal of our proposal is to investigate ZIKV blockade of JAK-STAT signaling as a mechanism for enhancing viral pathogenesis, vertical transmission and altering fetal neurodevelopment. These experiments are fundamental for understanding the pathogenesis of maternal-fetal transmission and fetal brain injury induced by ZIKV and will provide the necessary foundation for testing novel therapeutics and vaccines for fetal protection.

#### **NIH Spending Category**

**Biodefense Clinical Research Conditions Affecting the Embryonic and Fetal Periods Emerging Infectious Diseases Health Disparities Human Fetal Tissue Infectious Diseases** Injury (total) Accidents/Adverse Effects Injury - Childhood Injuries Minority Health **Perinatal Period - Conditions Originating in Perinatal Period Pregnancy Rare Diseases Pediatric Vector-Borne Diseases Stem Cell Research** Stem Cell Research - Nonembryonic - Human Women's Health

## **Project Terms**

**Acute Animal Model Antiviral Agents Applications Grants Americas** Anatomy **Animals** Cell physiology **Binding Cell Nucleus** Client **Complex** Area **Astrocytes Brain** Cells Culicidae **Cytokine Signaling Data Data Set** Development **Developmental Gene Disease Disease Outbreaks Epidemic Fetal Development Epithelial Eye Injuries Fetal Tissues Flavivirus Foundations** Gene Expression Profile **Heat-Shock Proteins 90** Goals

RePORT ) RePORTER 11/27/21, 5:18 AM

#### **▼** Back to Search Results

**Description** 





Publications

**Patents** 

**Outcomes** 

**Clinical Studies** 

**News and More** 

**History** 

**Similar Projects** 

## JAK-STAT Control of Zika Virus-Induced Fetal Injury

**Project Number Contact PI/Project Leader** 1R01Al143265-01A1 **ADAMS WALDORF, KRISTINA** 

M.Other Pls

**Awardee Organization UNIVERSITY OF WASHINGTON** 

# Details

**Contact PI/ Project Leader Other Pls Program Official** 

Name Name

MORABITO, KAITLYN MELISSA ADAMS WALDORF, KRISTINA M. **GALE, MICHAEL J** Title

**PROFESSOR** 

adamsk@u.washington.edu

# Name

dambachkm@mail.nih.gov

#### **Organization**

Contact

Department Type State Code Name **OBSTETRICS & GYNECOLOGY UNIVERSITY OF WASHINGTON** WA

City Organization Type **Congressional District SEATTLE SCHOOLS OF MEDICINE** 

Country **UNITED STATES (US)** 

#### **Other Information**

FOA Administering Institutes or Centers **Project Start** 01-July-2019 **NATIONAL INSTITUTE OF ALLERGY** PA-18-484 Date **AND INFECTIOUS DISEASES** Study Section Project End Date 30-June-2024 Special Emphasis Panel ZRG1 IDM-X **DUNS Number** CFDA Code 605799469 855 **Budget Start** 01-July-2019

Fiscal Year **Award Notice Date** 21-June-2019 2019

Date **Budget End Date** 30-June-2020

## **Project Funding Information for 2019**

**Total Funding Direct Costs Indirect Costs** \$919,950 \$609,116 \$310,834

Year	Funding IC	FY Total Cost by IC
2019	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$919.950

## **NIH Categorical Spending**

### **Click here for more information on NIH Categorical Spending**

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$441,576	Health Disparities; Minority Health;
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$919,950	Biodefense; Clinical Research; Conditions Affecting the Embryonic and Fetal Periods; Emerging Infectious Diseases; Human Fetal Tissue; Infectious Diseases; Injury (total) Accidents/Adverse Effects; Injury - Childhood Injuries; Neurosciences; Pediatric; Perinatal Period - Conditions Originating in Perinatal Period; Pregnancy; Rare Diseases; Stem Cell Research; Stem Cell Research - Nonembryonic - Human; Vector-Borne

# **品 Sub Projects**

No Sub Projects information available for 1R01Al143265-01A1



Diseases; Women's Health;

11/27/21, 5:18 AM RePORT ) RePORTER

**∢** Back to Search Results

**Description** 

**Details** 

Sub-Projects

Publications

**Patents** 

**Outcomes** 

**Clinical Studies** 

**News and More** 

<u>History</u>

Similar Projects

# **JAK-STAT Control of Zika Virus-Induced Fetal Injury**

**Project Number Contact PI/Project Leader ADAMS WALDORF, KRISTINA** 1R01Al143265-01A1 M.Other Pls

**Awardee Organization UNIVERSITY OF WASHINGTON** 

No Patents information available for 1R01Al143265-01A1

## Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 1R01Al143265-01A1

## **Clinical Studies**

No Clinical Studies information available for 1R01Al143265-01A1

# News and More

#### **Related News Releases**

No news release information available for 1R01AI143265-01A1

# ← History

No Historical information available for 1R01AI143265-01A1

# **Similar Projects**

No Similar Projects information available for 1R01Al143265-01A1